3-triazol-1-yl]-alfa-D-galactopyranoside clinical trials

An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

This study looks at a new drug, GB1211, combined with an existing one, atezolizumab (Tecentriq), for non-small cell lung cancer. Researchers want to see if this combination is safe and how well it works to shrink tumours or stop them from growing. It involves different study parts.